Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01422603

Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)

A Pilot Study of Clofarabine Pre-conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia.

Sponsor: Genzyme, a Sanofi Company

Conditions Acute Myeloid Leukaemia Myelodysplasia

Interventions Clofarabine

Updated 6 times since 2017 Last updated: Sep 5, 2018 Started: Feb 28, 2011 Primary completion: May 31, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Myeloid Leukaemia and Myelodysplasia and is currently completed. Genzyme, a Sanofi Company leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company
University Hospital Southampton NHS Foundation Trust

Data source: University Hospital Southampton NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Southampton, United Kingdom